Company Research
Whether you are exploring new sales opportunities or researching a new investment, FirstRain provides unique insight into important developments for King Pharmaceuticals, Inc. (KG). You can receive reports or configure the research engine for yourself.
Report On:
King Pharmaceuticals, Inc. (KG)
HEALTHCARE - Drugs - Drug Manufacturers - Other
Generated: Wednesday March 23, 2011 04:20 AM
|
|
||||||||||||||||||
Quotes About King Pharmaceuticals, Inc.
-
Pfizer recalls pain drug acquired in King deal
There are other assets that make this a good deal for us. It expands our pain portfolio, both of marketed products and ones in registration,"
- Joan Campion -
A Big Pain For Pfizer: Embeda Is Recalled
With the addition of King's talented colleagues and innovative products and technology, Pfizer will offer patients who are in need of pain relief and pain management a broader spectrum of treatment options," -
Pfizer Animal Health expands poultry offering following King merger
Our customers will continue to benefit from the skill and expertise of our field team, our industry-leading programmes and services and unwavering customer focus."
- Jose Francisco Ortiz -
Pfizer Animal Health acquisition of Alpharma expands poultry portfolio
The integration expands Pfizer Poultry Health's product portfolio and broadens the range of healthcare solutions we can offer our poultry customers. It allows us to enter new therapeutic fields and deliver increased expertise to poultry producers," -
Pfizer acquires King Pharma
Pfizer's expanded portfolio also includes King's Meridian auto- injector business for emergency drug delivery, which develops and manufactures the EpiPen, and its Alpharma animal health business, both of which are complementary to and aligned with Pfizer's existing businesses,"
- Ian Read
Latest Company Intelligence
-
Pfizer Inc. Recalls Pain Drug Acquired in King Pharmaceuticals??, Inc. Deal
BioSpace | Mar 17,'11
(Reuters) - Just weeks after completing its $3.6 billion purchase of King Pharmaceuticals, Pfizer Inc has recalled an opioid painkiller obtained in the deal and said it could remain unavailable for many months because of formulation problems. -
Embeda Recall Issued Due to Ongoing Manufacturing Problems
AboutLawsuits.com | Mar 17,'11
Manufacturing problems have led to the recall of Embeda, a morphine-based painkiller plagued with production problems over the last year. The Embeda recall was announced this week by Pfizer subsidiary King Pharmaceuticals, after the drug failed to meet stability requirements during testing. The company says that the problem is unlikely to constitute a health risk to patients and there -
Chronic Pain Drug Embeda Recalled
Osteoarthritis - About.com | Mar 16,'11
Embeda ( morphine sulfate and naltrexone hydrochloride) has been voluntarily recalled by King Pharmaceuticals, a subsidiary of Pfizer. The recall affects all dosages of Embeda Extended Release Capsules and was initiated when a stability requirement was not met during routine testing of the drug. Although the issue does not likely jeopardize the safety of patients taking the drug as -
How Pfizer's Breakup Plan May Explain Sudden Exit of Former CEO
Placebo Effect - BNET | Mar 16,'11
Jim Edwards, a former managing editor of Adweek, has covered drug marketing at Brandweek for four years, and is a former Knight-Bagehot fellow at Columbia University's business and journalism schools. Is it any coincidence that Pfizer (PFE) CEO Ian Read (top) proposed breaking off 40 percent of the company just weeks after former chief Jeff Kindler left the company without warning on a -
Embeda pain reliever recalled
ConsumerReports.org | Mar 16,'11
All doses of the prescription drug Embeda, a potent combination of morphine and naltrexone used to treat moderate to severe chronic pain, have been recalled, according to an announcement from the manufacturer, King Pharmaceuticals. The company said that while the drug is not not known to pose any immediate risks to patients, it failed stability tests, which measure how it responds to -
A Big Pain For Pfizer: Embeda Is Recalled
Pharmalot | Mar 15,'11
Less than two weeks after closing the deal to buy King Pharmaceuticals, Pfizer is now voluntarily recalling all dosages and lots of the Embeda painkiller due to stability requirements that were not met during routine testing. And the problem may take several months to resolve. The move, which was disclosed in a statement today on the Embeda web site , is a blow to the drugmaker, which
FirstRain customers use intelligent business search to find actionable insights about companies, management, and industries. You can review company briefs, quickly research a new idea or opportunity, generate personalized industry reports, or set up alerts on reasons to call. Be sure to view our sample reports below.
